HRP20010042B1 - Newcastle disease virus infectious clones, vaccines and diagnostic assays - Google Patents

Newcastle disease virus infectious clones, vaccines and diagnostic assays

Info

Publication number
HRP20010042B1
HRP20010042B1 HR20010042A HRP20010042A HRP20010042B1 HR P20010042 B1 HRP20010042 B1 HR P20010042B1 HR 20010042 A HR20010042 A HR 20010042A HR P20010042 A HRP20010042 A HR P20010042A HR P20010042 B1 HRP20010042 B1 HR P20010042B1
Authority
HR
Croatia
Prior art keywords
vaccines
newcastle disease
disease virus
diagnostic assays
virus infectious
Prior art date
Application number
HR20010042A
Other languages
English (en)
Croatian (hr)
Inventor
Petrus Hubertus Peeters Bernardus
Sven De Leeuw Olav
Koch Guus
Leonard Josef Gielkens Arnoud
Original Assignee
Stichting Dienst Landbouwkundig Onderzoek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8233832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20010042(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stichting Dienst Landbouwkundig Onderzoek filed Critical Stichting Dienst Landbouwkundig Onderzoek
Publication of HRP20010042A2 publication Critical patent/HRP20010042A2/hr
Publication of HRP20010042B1 publication Critical patent/HRP20010042B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HR20010042A 1998-06-19 2001-01-15 Newcastle disease virus infectious clones, vaccines and diagnostic assays HRP20010042B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98202054A EP0974660A1 (de) 1998-06-19 1998-06-19 Newcastle-Krankheitsvirus Infektiöser Klone, Impfstoffe und Diagnosetest
PCT/NL1999/000377 WO1999066045A1 (en) 1998-06-19 1999-06-17 Newcastle disease virus infectious clones, vaccines and diagnostic assays

Publications (2)

Publication Number Publication Date
HRP20010042A2 HRP20010042A2 (en) 2001-12-31
HRP20010042B1 true HRP20010042B1 (en) 2011-03-31

Family

ID=8233832

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010042A HRP20010042B1 (en) 1998-06-19 2001-01-15 Newcastle disease virus infectious clones, vaccines and diagnostic assays

Country Status (28)

Country Link
US (3) US6719979B2 (de)
EP (2) EP0974660A1 (de)
JP (3) JP2002518012A (de)
KR (1) KR20010053000A (de)
CN (2) CN101275142A (de)
AR (1) AR020091A1 (de)
AT (1) ATE367442T1 (de)
AU (1) AU754844B2 (de)
BR (1) BR9911383A (de)
CA (1) CA2334165A1 (de)
CZ (1) CZ300760B6 (de)
DE (1) DE69936585T2 (de)
DK (1) DK1088077T3 (de)
EA (1) EA004796B1 (de)
ES (1) ES2291029T3 (de)
HR (1) HRP20010042B1 (de)
HU (1) HUP0102429A3 (de)
ID (1) ID27343A (de)
IL (2) IL140381A0 (de)
NO (1) NO329193B1 (de)
NZ (1) NZ508982A (de)
PL (1) PL197722B1 (de)
PT (1) PT1088077E (de)
SI (1) SI1088077T1 (de)
TR (1) TR200100350T2 (de)
UA (1) UA77146C2 (de)
WO (1) WO1999066045A1 (de)
ZA (1) ZA200100241B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974660A1 (de) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle-Krankheitsvirus Infektiöser Klone, Impfstoffe und Diagnosetest
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
AU4971500A (en) * 1999-05-05 2000-11-21 University Of Maryland Production of novel newcastle disease virus strains from cdnas and improved liveattenuated newcastle disease vaccines
US10383936B2 (en) * 1999-05-05 2019-08-20 University Of Maryland, College Park Infectious laryngotracheitis virus (ILTV) vaccine using recombinant newcastle disease virus vector
CA2312626A1 (en) * 1999-07-27 2001-01-27 Akzo Nobel N.V. A recombinant newcastle disease virus as an embryo vaccine
EP1074614B1 (de) * 1999-07-27 2004-07-07 Akzo Nobel N.V. Rekombinantes Newcastle-Krankheitsvirus zur in ovo Impfung
DK1297110T3 (da) 2000-06-23 2009-11-16 Intervet Int Bv Attenueret bovin respiratorisk syncytialvirus
DK1383795T3 (da) * 2000-11-02 2007-05-29 Intervet Int Bv Rekombinant nucleoproteinmutant fra Newcastle disease-virus som markörvaccine
KR100437888B1 (ko) * 2001-07-30 2004-07-03 주식회사 인트론바이오테크놀로지 뉴캐슬병 바이러스 검출용 프라이머 및 상기 프라이머를이용한 뉴캐슬병 바이러스 검출, 병원성 및 유전형 조사방법
US7615209B2 (en) 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
ATE307606T1 (de) * 2001-10-04 2005-11-15 Ct Voor Onderzoek In Diergenee Abgeschwächter mutantenstamm eines virus der newcastle-krankheit für eine in ovo impfung und dessen benutzung
WO2003072725A2 (en) * 2002-02-21 2003-09-04 Mount Sinai School Of Medicine Recombinant negative strand virus rna expression systems and vaccines
TW200502402A (en) * 2002-12-06 2005-01-16 Wyeth Corp Escape mutants of newcastle disease virus as marker vaccines
JP2007526215A (ja) * 2003-05-05 2007-09-13 ダウ アグロサイエンス リミテッド ライアビリティー カンパニー トランスジェニック植物細胞に由来する安定な免疫予防的および治療的組成物ならびにその産生方法
AU2004235813B2 (en) * 2003-05-05 2010-07-29 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
US7270990B2 (en) 2003-06-20 2007-09-18 Microbix Biosystems, Inc. Virus production
US7527638B2 (en) 2003-12-16 2009-05-05 Depuy Spine, Inc. Methods and devices for minimally invasive spinal fixation element placement
MY146476A (en) 2004-06-24 2012-08-15 Boehringer Ingelheim Vetmed Method of diagnosing lawsonia intracellularis
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
KR20070085314A (ko) 2004-11-12 2007-08-27 바이엘 쉐링 파마 악티엔게젤샤프트 재조합 뉴캐슬 질환 바이러스
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
PT2529747T (pt) * 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
EP1996610A1 (de) * 2006-03-15 2008-12-03 Intervet International BV Rekombinantes newcastle-krankheit-virus, das h5-hemagglutinin des vogelgrippenvirus exprimiert
MX2008011727A (es) * 2006-03-15 2008-12-10 Intervet Int Bv Vectores de virus mononegaviral recombinantes.
KR100776398B1 (ko) * 2006-03-23 2007-11-28 주식회사 고려비엔피 조류 ｈｎ 단백질의 에피토프 및 상기 변이 에피토프를포함하는 뉴캐슬병 바이러스
KR100801180B1 (ko) 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
KR100874256B1 (ko) 2007-02-12 2008-12-16 대한민국 대장균 내독소 단백질 및 뉴캐슬병 바이러스뉴라미니데이즈 에피토프의 융합단백질 및 이의 용도
KR100955502B1 (ko) * 2007-11-30 2010-04-30 대한민국 병원성 뉴캐슬병 바이러스 항체와 특이적으로 반응하는펩타이드 및 그의 용도
EP2085092A1 (de) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Abgeschwächte onkolytische Paramyxoviren zur Kodierung von Vogel-Zytokinen
US7794714B2 (en) * 2008-03-14 2010-09-14 The United States Of America As Represented By The Secretary Of Agriculture Newcastle disease virus monoclonal antibodies
US20090258035A1 (en) * 2008-03-21 2009-10-15 The United States Of America, As Represented By The Secretary Of Agriculture Avian virus vaccines and uses thereof
JP2012509308A (ja) * 2008-11-19 2012-04-19 ラボラトリオ アヴィメキシコ エスエー ディーイー シーヴィー 遺伝子組み換え不活性化ウィルスベクターワクチン
EP2987856B1 (de) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimäre newcastle-krankheitsviren und verwendungen davon
CA2771540C (en) * 2009-08-21 2019-01-15 Merial Limited Recombinant avian paramyxovirus vaccine and method for making and using thereof
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
ES2380289T3 (es) 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
WO2012151391A2 (en) 2011-05-04 2012-11-08 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
US9265813B2 (en) 2011-10-27 2016-02-23 Wellstat Ophthalmics Corporation Vectors encoding rod-derived cone viability factor
SI2785373T1 (sl) 2011-11-30 2020-02-28 Boehringer Ingelheim Animal Health USA Inc. Rekombinantni vektorji HVT, ki izražajo antigene aviarnih patogenov in uporabe le-teh
KR101374192B1 (ko) * 2011-12-21 2014-03-14 대한민국 제4형 조류파라믹소바이러스 ｈｎ 단백질 및 이를 포함하는 ｈｉ법 검사용 항원진단액
GEP20196976B (en) 2013-03-14 2019-06-10 Sloan Kettering Cancer Center Memorial Newcastle disease viruses and uses thereof
CN104059942B (zh) * 2013-03-20 2016-12-28 湖北省农业科学院畜牧兽医研究所 新城疫病毒耐热活疫苗载体系统及其应用
US20140341950A1 (en) * 2013-05-15 2014-11-20 University Of Georgia Research Foundation, Inc. Recombinant avian paramyxovirus vaccine and method for making and using thereof
EP3441084A1 (de) 2014-02-27 2019-02-13 Viralytics Limited Onkolytisches virus und immunstimulator zur kombinationsbehandlung von krebs
US10780158B2 (en) 2015-11-16 2020-09-22 Georgia State University Research Foundation, Inc. Tunable vaccine platform against pathogens of the paramyxovirus family
US10063211B2 (en) * 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
RU2022108149A (ru) 2016-02-03 2022-05-05 СиДжи ДИСКАВЕРИ, ИНК. Композиции гемагглютинина гриппа с гетерологичными эпитопами и/или измененными сайтами расщепления при созревании
US10196616B2 (en) 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof
CA3088906A1 (en) * 2018-02-28 2019-09-06 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
US20200297787A1 (en) * 2018-07-13 2020-09-24 Icahn School Of Medicine At Mount Sinai Apmv and uses thereof for the treatment of cancer
CN109735552A (zh) * 2019-02-27 2019-05-10 苏州世诺生物技术有限公司 禽新城疫病毒新型基因工程亚单位疫苗
CN110018304A (zh) * 2019-05-15 2019-07-16 河南省农业科学院 一种新城疫抗体阻断检测试纸
CN110240635B (zh) * 2019-06-10 2022-04-22 华中农业大学 检测新城疫病毒抗体的多肽及其elisa检测试剂盒
CN110257562A (zh) * 2019-07-31 2019-09-20 河北农业大学 一种raa-lfd检测鸡传染性喉气管炎病毒的引物和探针组合及其应用
KR102154796B1 (ko) * 2019-10-18 2020-09-22 주식회사 바이오포아 변이 뉴캣슬병 바이러스 및 상기 바이러스를 이용한 조류 백신
CN110938711A (zh) * 2019-12-20 2020-03-31 河北农业大学 一种检测鸡传染性喉气管炎病毒的实时荧光raa引物和探针、试剂盒及其使用方法
CN111334528B (zh) * 2020-03-20 2022-02-18 山东农业大学 水貂肠炎细小病毒全基因组感染性克隆及其构建方法和应用
CN112048484A (zh) * 2020-07-27 2020-12-08 华南农业大学 一株表达传染性法氏囊强毒株vp2蛋白的基因ⅶ型新城疫重组病毒和疫苗
CN114214338B (zh) * 2021-08-26 2023-02-03 扬州大学 猪源piv5全长感染性克隆及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0780475A1 (de) * 1995-08-09 1997-06-25 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Dem Genom von minussträngigen RNA-Viren entsprechende CDNA und Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
EP1394259A3 (de) 1994-07-18 2004-04-14 Karl-Klaus Prof. Dr. Conzelmann Rekombinantes infektiöses nicht-in-Segmente-geteiltes negativ-Strange-RNS-Virus
AU729518B2 (en) * 1995-06-07 2001-02-01 Syntro Corporation Recombinant fowlpox viruses and uses thereof
EP0839912A1 (de) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Ansteckende Klone von RNA-Viren und darauf basierende Impfstoffe und diagnostisches Verfahren
EP0974660A1 (de) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle-Krankheitsvirus Infektiöser Klone, Impfstoffe und Diagnosetest
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0780475A1 (de) * 1995-08-09 1997-06-25 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Dem Genom von minussträngigen RNA-Viren entsprechende CDNA und Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren

Also Published As

Publication number Publication date
EA200100057A1 (ru) 2001-08-27
ZA200100241B (en) 2002-06-26
PT1088077E (pt) 2007-10-29
DE69936585D1 (de) 2007-08-30
EP0974660A1 (de) 2000-01-26
IL140381A (en) 2008-06-05
ES2291029T3 (es) 2008-02-16
UA77146C2 (en) 2006-11-15
HUP0102429A2 (hu) 2001-10-28
EA004796B1 (ru) 2004-08-26
JP2002518012A (ja) 2002-06-25
JP2006141398A (ja) 2006-06-08
AU4399199A (en) 2000-01-05
US7332169B2 (en) 2008-02-19
NO329193B1 (no) 2010-09-13
NZ508982A (en) 2003-07-25
JP2009261387A (ja) 2009-11-12
EP1088077B2 (de) 2012-03-21
US20040235134A1 (en) 2004-11-25
IL140381A0 (en) 2002-02-10
TR200100350T2 (tr) 2001-06-21
DE69936585T2 (de) 2008-04-30
US20030087417A1 (en) 2003-05-08
NO20006406L (no) 2001-02-19
NO20006406D0 (no) 2000-12-15
CN101275142A (zh) 2008-10-01
HRP20010042A2 (en) 2001-12-31
DK1088077T3 (da) 2007-11-12
ID27343A (id) 2001-04-05
CA2334165A1 (en) 1999-12-23
US7547442B2 (en) 2009-06-16
BR9911383A (pt) 2001-03-13
US20040234552A1 (en) 2004-11-25
CZ300760B6 (cs) 2009-08-05
AU754844B2 (en) 2002-11-28
CZ20004707A3 (en) 2001-05-16
HUP0102429A3 (en) 2003-12-29
KR20010053000A (ko) 2001-06-25
WO1999066045A1 (en) 1999-12-23
PL348300A1 (en) 2002-05-20
PL197722B1 (pl) 2008-04-30
CN1314942A (zh) 2001-09-26
EP1088077A1 (de) 2001-04-04
US6719979B2 (en) 2004-04-13
EP1088077B1 (de) 2007-07-18
SI1088077T1 (sl) 2008-02-29
ATE367442T1 (de) 2007-08-15
AR020091A1 (es) 2002-04-10

Similar Documents

Publication Publication Date Title
HRP20010042B1 (en) Newcastle disease virus infectious clones, vaccines and diagnostic assays
CA2366072A1 (en) Prrsv vaccines
HUP9903829A3 (en) Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof
HUP0303036A3 (en) Dna transfection system for the generation of infectious influenza virus
ATE287728T1 (de) Adjuvierte rekombinante lebendimpfstoffe gegen influenza- oder herpesviren
BR9710012A (pt) Vacina viva recombinante à base de herpesvírus canino notadamente contra o mal de carré a raiva ou o vírus parainfluenza do tipo 2
BR9807873A (pt) Vacinas de flavivìrus quiméricos
DK0702085T4 (da) Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
HUP0302265A2 (hu) Rekombináns Newcastle-betegségvírus nukleoprotein-mutánsa markervakcinaként alkalmazva
AR040996A1 (es) Acidos nucleicos inmunoestimuladores
DE69533305D1 (de) Lebende rekombinante Vogelvakzine auf eines Vogelherpesvirus gegründet, gegen Gumborokrankheit
BR0016145A (pt) Clones infecciosos
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
BR0012433A (pt) Vìrus recombinante, infeccioso de doença bursal infecciosa, método para obter o mesmo, ibdv mosaico infeccioso (mibdv), e, vacina
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
BR0102322A (pt) Vìrus de uma cepa de vìrus de doença bursal infecciosa, vacina contra doença bursal infecciosa, métodos para a preparação do vìrus, e da vacina, e, uso do vìrus
BR9915703B1 (pt) mutante do vìrus da raiva recombinante, e, vacina anti-rábica atenuada viva.
HUP0101652A1 (hu) Új kompozíció
ES2153284B1 (es) Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
EP1296710A4 (de) Rekombinanter impfstoff gegen das für die bursal-krankheit verantwortliche virus(03.01.02)
AU1674200A (en) Dna vaccine against infectious bursal disease virus
DE69029145D1 (de) Für die infektiöse erkrankung der bursa fabricius verantwortlicher virus
DE60316701D1 (de) Hühner-astrovirus typ 2
IT1295542B1 (it) Bocchetta di presa d'aria anti-vento
HU0102823D0 (en) A broad spectrum infectious bursal disease virus vaccine

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK, NL

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110614

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20120618